Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience
JPGN Reports · 2026-11 · 7 (4) · 536-543
DOI: 10.1002/jpr3.70208 ↗Kurz gefasst
Fachartikel in der Zeitschrift JPGN Reports, online erschienen am 16.07.2026. Verfasst von Cher Wei Chuah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology The Children's Hospital at Westmead Westmead Australia. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy.
Methods
A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January 2019 to December 2021. Proactive TDM was performed at induction, end of induction and 6‐monthly thereafter. The primary outcome was switching to a different biologic as a marker of treatment failure. Secondary outcomes of a physician global assessment (PGA) scale, calprotectin, albumin and C‐reactive protein (CRP) levels were collected at induction, end of induction, 1‐year and 2‐year timepoints.
Results
Seventy‐nine patients were included (62% male, median age 13 years). Durability was 96% at 1 year and 88% at 2 years. Nine patients switched biologics with a median time of 57 weeks. Predictors of therapy failure included the need for escalated induction (odds ratio [OR] 8.5, p = 0.01) colonic phenotype (OR 9.7, p < 0.01), and post‐induction calprotectin level above 305 μg/g (positive predictive value 36%) were identified.
Conclusions
Utilizing a proactive TDM results in excellent durability of IFX at 2 years in paediatric CD. Colonic phenotype is an independent predictor for IFX failure, highlighting the need for directed therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology The Children's Hospital at Westmead Westmead Australia.
- Sydney Adventist Hospital Clinical School, School of Medicine and Psychology Australian National University Canberra Australia.
- School of Medicine University of Sydney Sydney Australia.
- Children's Hospital Westmead Clinical School, Sydney School of Medicine University of Sydney Sydney Australia.
ORCID-Profile: Cher Wei Chuah
Zitieren
APA
Chuah, C. W., Eldredge, J., Magoffin, A., O'Loughlin, E. V., Park, C. J., Puppi, J., Siew, S., Stormon, M., Thacker, K., & Dutt, S. (2026). Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience. JPGN Reports, 7(4), 536-543. https://doi.org/10.1002/jpr3.70208
Vancouver
Chuah CW, Eldredge J, Magoffin A, O'Loughlin EV, Park CJ, Puppi J, et al. Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience. JPGN Reports. 2026;7(4):536-543. doi:10.1002/jpr3.70208
BibTeX
@article{Chuah2026,
author = {Chuah, Cher Wei and Eldredge, Jessica and Magoffin, Annabel and O'Loughlin, Edward Vincent and Park, Calvin Joomann and Puppi, Juliana and Siew, Susan and Stormon, Michael and Thacker, Kunal and Dutt, Shoma},
title = {Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience},
journal = {JPGN Reports},
year = {2026},
volume = {7},
number = {4},
pages = {536--543},
doi = {10.1002/jpr3.70208}
}
EUVIMED